PGPIPN vs Larazotide Acetate
Side-by-side comparison of key properties, dosing, and research.
Immune Support
PGPIPNRecovery & Repair
Larazotide Acetate- Summary
- PGPIPN is a bioactive hexapeptide (Pro-Gly-Pro-Ile-Pro-Asn) derived from beta-casein during enzymatic digestion. It exhibits anti-inflammatory properties via opioid receptor modulation and cytokine suppression, making it relevant for gut health, systemic inflammation, and as a component of casein-derived functional foods.
- Larazotide acetate is an 8-amino acid peptide (Gly-Gly-Val-Leu-Val-Gln-Pro-Gly) derived from Zonula Occludens Toxin (ZOT) of Vibrio cholerae. It paradoxically acts as a ZOT antagonist to close tight junctions and reduce intestinal permeability ('leaky gut'). It is the most advanced clinical compound targeting gut permeability directly.
- Half-Life
- Estimated 30-120 minutes (peptide degradation)
- Local gut action; minimal systemic exposure
- Admin Route
- Oral, Subcutaneous (research)
- Oral
- Research
- —
- —
- Typical Dose
- 200-500 mg per day
- 0.5-2 mg
- Frequency
- Once or twice daily
- 3x daily
- Key Benefits
- Anti-inflammatory effects via cytokine suppression
- Gut mucosal protection and intestinal barrier support
- Opioid receptor modulation for gut motility regulation
- Potential analgesic activity via central and peripheral opioid pathways
- Explored for inflammatory bowel conditions and gut dysbiosis
- Natural origin (food-derived) with favorable safety profile
- Directly reduces intestinal tight junction permeability
- Clinical efficacy in celiac disease (Phase 3 trials)
- Reduces systemic inflammation from gut permeability
- Targets root cause of leaky gut (Zonulin pathway)
- Local gut action without systemic absorption
- Potential application in IBS, IBD, autoimmune conditions
- Side Effects
- Generally very well-tolerated given food-derived origin
- Theoretical opioid-mediated constipation at high doses
- Rare milk protein allergy in casein-sensitive individuals
- Headache (mild, dose-dependent)
- Nausea (rare)
- Well-tolerated overall in clinical trials
- Stacks With
- —
- —